Elevated serum osteopontin level is associated with blood eosinophilia and asthma comorbidity in patients with allergic rhinitis Wenlong Liu, MD, Wentong.

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion William T. Barchuk, MD, Anne Marie Salapatek,

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Critical link between glycogen synthase kinase 3β and forkhead box P3 in patients with chronic rhinosinusitis with nasal polyps Xingmei Wu, MD, Sihua.

The antimicrobial protein short palate, lung, and nasal epithelium clone 1 (SPLUNC1) is differentially modulated in eosinophilic and noneosinophilic chronic.

Akos Heinemann, MD, Gunter J. Sturm, MD, Martina Ofner, BSc, Eva M

Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil.

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

Proviral integration site for Moloney murine leukemia virus 1, but not phosphatidylinositol-3 kinase, is essential in the antiapoptotic signaling cascade.

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis Friedrich Horak, MD, Kamal D.

Is 9 more than 2 also in allergic airway inflammation?

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study Peter Kenney, BSc, Ole Hilberg,

Children with allergic and nonallergic rhinitis have a similar risk of asthma Bo Lund Krogsgaard Chawes, MD, Klaus Bønnelykke, MD, PhD, Eskil Kreiner-Møller,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosis Maya Zimmermann, PhD, Andrea Koreck, MD, Norbert.

Toll-like receptor 3 enhances late-phase reaction of experimental allergic conjunctivitis Mayumi Ueta, MD, PhD, Satoshi Uematsu, MD, PhD, Shizuo Akira,

Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy Weiping Wen, PhD, Wenlong Liu, MD, Luo Zhang, PhD, Jing Bai,

Thymic stromal lymphopoietin activation of basophils in patients with allergic asthma is IL-3 dependent Brittany M. Salter, BSc, John Paul Oliveria,

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

The National Biome Initiative: An allergy perspective

Peter M. Wolfgram, MD, David B. Allen, MD

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Reply Journal of Allergy and Clinical Immunology

Ordinary vibratory angioedema is not generally associated with ADGRE2 mutation Zuotao Zhao, MD, PhD, Sascha Reimann, MD, Shan Wang, MD, Yuhan Wang, MD,

A lower prevalence of asthma among patients with chronic rhinosinusitis in southern China Yunping Fan, MD, PhD, Shuli Chen, MD, PhD, Xiujuan Qu, MD,

A novel allergen-specific therapy with CD40-silenced B cells and dendritic cells Motohiko Suzuki, MD, PhD, Makoto Yokota, MD, PhD, Yoshihisa Nakamura,

Rhinophototherapy: A new therapeutic tool for the management of allergic rhinitis Andrea I. Koreck, MD, PhD, Zsanett Csoma, MD, Laszlo Bodai, Ferenc Ignacz,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

What are the best outcome measurements for atopic eczema

Lung function trajectories from birth through puberty reflect asthma phenotypes with allergic comorbidity Karin C. Lødrup Carlsen, MD, PhD, Petter Mowinckel,

The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ or CD8+ T cells Juha Punnonen, MD, PhD, Hans Yssel, PhD,

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion William T. Barchuk, MD, Anne Marie Salapatek,

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Staphylococcal exotoxins are strong inducers of IL-22: A potential role in atopic dermatitis Margarete Niebuhr, MD, Helena Scharonow, MS, Merle Gathmann,

Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

What is an “eosinophilic phenotype” of asthma?

Increased activation-induced cell death of high IFN-γ–producing TH1 cells as a mechanism of TH2 predominance in atopic diseases Tunc Akkoc, PhD, Pieter.

Enhanced CD46-induced regulatory T cells suppress allergic inflammation after Dermatophagoides pteronyssinus–specific immunotherapy Yi-Giien Tsai, MD,

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

High prevalence of severe asthma in a large random population study

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.

Sara Paveglio, PhD, MS, Erin Bennett, MS, Kelly L. Hawley, PhD, Adam P

Peach allergy in China: A dominant role for mugwort pollen lipid transfer protein as a primary sensitizer Zhong-Shan Gao, PhD, Zhao-Wei Yang, BSc, Shan-Dong.

Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Leukotriene D4 induces gene expression in human monocytes through cysteinyl leukotriene type I receptor Grzegorz Woszczek, MD, PhD, Li-Yuan Chen, PhD,

Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis Carmen Rondón, MD, PhD, Javier.

Human rhinovirus infection enhances airway epithelial cell production of growth factors involved in airway remodeling Richard Leigh, MBChB, PhD, Wale.

Machine learning, natural language programming, and electronic health records: The next step in the artificial intelligence journey? Neil Mehta, MBBS,

Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis Philippe-Jean Bousquet, MD, Christophe Combescure, PhD,

Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Inflammation-mediated upregulation of centrosomal protein 110, a negative modulator of ciliogenesis, in patients with chronic rhinosinusitis Yinyan Lai,

Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy– treated mother Sabine Flicker, PhD, Katharina Marth, MD, Heinz.

Kinase inhibitors in clinical practice: An expanding world

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Systemic responses after bronchial aspirin challenge in sensitive patients with asthma Joanna S. Makowska, MD, PhD, Janina Grzegorczyk, PhD, Barbara Bienkiewicz,

Role of Art v 3 in pollinosis of patients allergic to Pru p 3

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Elevated serum osteopontin level is associated with blood eosinophilia and asthma comorbidity in patients with allergic rhinitis Wenlong Liu, MD, Wentong Xia, MD, Yunping Fan, PhD, Hongtian Wang, MD, Kejun Zuo, PhD, Yinyan Lai, PhD, Huabin Li, MD, PhD, Zheng Liu, MD, PhD, Jianbo Shi, MD, PhD, Geng Xu, MD, PhD Journal of Allergy and Clinical Immunology Volume 130, Issue 6, Pages 1416-1418.e6 (December 2012) DOI: 10.1016/j.jaci.2012.06.010 Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 The association between serum OPN concentration and TNSS and other biomarker levels in patients with AR. Serum OPN concentration was positively associated with TNSS (A) and blood EOS number (B), as well as serum ECP (C) and IL-5 levels (D) in patients with AR. Moreover, serum OPN concentration (E), blood EOS number (F), and serum ECP (G) and IL-5 (H) levels were positively associated with concomitant asthma (AS+) in patients with AR. *P < .05, compared with patients with AR without asthma (AS−). AS, Asthma; TNSS, total nasal symptom score. Journal of Allergy and Clinical Immunology 2012 130, 1416-1418.e6DOI: (10.1016/j.jaci.2012.06.010) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 The association between serum OPN concentration and VAS score in patients with AR. Serum OPN concentration was positively associated with the VAS score in patients with AR. *P < .05. VAS, Visual analog scale. Journal of Allergy and Clinical Immunology 2012 130, 1416-1418.e6DOI: (10.1016/j.jaci.2012.06.010) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E2 The association between serum OPN concentration and disease duration in patients with AR. Serum OPN concentration was positively associated with disease duration in patients with OR. There were significant differences in OPN levels among 3 groups of patients with AR. The OPN level in group III was significantly higher than in groups II and I (group III, duration >5 years; group II, 5 years ≥duration ≥3 years; group I, duration <3 years). *P < .05. Journal of Allergy and Clinical Immunology 2012 130, 1416-1418.e6DOI: (10.1016/j.jaci.2012.06.010) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E3 Recombinant human OPN (rh-OPN) enhanced chemotaxis of purified blood EOS in vitro. Rh-OPN (0-1 μg/mL) significantly enhanced EOS chemotaxis in a dose-dependent manner after stimulation for 12 hours (A); EOS migration has been significantly enhanced by rh-OPN (1 μg/mL), which was similar to the effect induced by 1 μg/mL of recombinant human eotaxin as the positive control; this effect was significantly inhibited by anti-OPN mAb (1 μg/mL) (B). The data indicated the means (SEM) of 3 independent experiments. *P < .05, compared with the control group; #P < .05, compared with the 0.05 μg/mL group; ##P < .05, compared with the with the 0.1 μg/mL group. Journal of Allergy and Clinical Immunology 2012 130, 1416-1418.e6DOI: (10.1016/j.jaci.2012.06.010) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E4 Recombinant human OPN (rh-OPN) enhanced ECP production of purified blood EOS in vitro. Rh-OPN (0-1 μg/mL) significantly increased the ECP level released by EOS in a dose-dependent manner after stimulation for 24 hours (A). The activated effect of rh-OPN was significantly inhibited by anti-OPN mAb (1 μg/mL) and phosphatidylinositol 3-kinase inhibitor, LY294002 (10 μM) (B). The data indicated the means (SEM) of 3 independent experiments. *P < .05, compared with the control group; #P < .05, compared with the 0.05 μg/mL group; ##P < .05, compared with the 0.1 μg/mL group. Journal of Allergy and Clinical Immunology 2012 130, 1416-1418.e6DOI: (10.1016/j.jaci.2012.06.010) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions